International Journal of Hematology最新文献_第5页

Extramedullary disease in multiple myeloma at diagnosis and over the course of the disease. 多发性骨髓瘤诊断时和病程中的髓外疾病。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-03-03 DOI: 10.1007/s12185-025-03958-6

Murad Guliyev, Ali Tunc, Umut Yılmaz, Selin Kucukyurt, Deniz Ozmen, Tugrul Elverdi, Ahmet Emre Eskazan, Muhlis Cem Ar, Yıldız Aydın, Ayse Salihoglu

{"title":"Extramedullary disease in multiple myeloma at diagnosis and over the course of the disease.","authors":"Murad Guliyev, Ali Tunc, Umut Yılmaz, Selin Kucukyurt, Deniz Ozmen, Tugrul Elverdi, Ahmet Emre Eskazan, Muhlis Cem Ar, Yıldız Aydın, Ayse Salihoglu","doi":"10.1007/s12185-025-03958-6","DOIUrl":"https://doi.org/10.1007/s12185-025-03958-6","url":null,"abstract":"Extramedullary disease (EMD) is an aggressive manifestation of multiple myeloma (MM) and is categorized into two distinct types: extramedullary-bone-related (EM-B) and extramedullary-extraosseous (EM-E). We aimed to investigate differences in the characteristics of disease and outcomes between these two types. This single-center, retrospective study included 132 patients with EMD who were diagnosed with MM between January 2010 and January 2020. Patients were divided into EM-B (n = 93) and EM-E (n = 39), and clinicopathological features and survival outcomes were analyzed. EMD was observed in 98 (74.2%) patients at initial diagnosis and in 34 (25.8%) during a relapse. EM-E was significantly associated with ≥ 2 involved sites, high bone marrow plasma cell percentage, high LDH and beta-2 microglobulin levels, anemia, and high-risk fluorescence in situ hybridization abnormalities compared to EM-B. Patients with EM-E had significantly shorter progression-free survival and overall survival than those with EM-B. Anemia, hypercalcemia, high LDH, EMD at relapse, ≥ 2 involved sites, and not receiving autologous stem cell transplantation were independent poor risk factors for survival. In conclusion, EMD is a heterogeneous entity, and this study demonstrated that patients with EM-E presented with different clinicopathological characteristics and had worse survival compared to those with EM-B.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143541979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chimerism analysis by ABO blood group genotyping with digital droplet PCR. 用数字液滴PCR进行ABO血型基因分型的嵌合分析。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-03-01 Epub Date: 2024-12-17 DOI: 10.1007/s12185-024-03898-7

Takuya Naruto, Maiko Sagisaka, Mieko Ito, Akiko Hayashi, Naoyuki Miyagawa, Dai Keino, Tomoko Yokosuka, Fuminori Iwasaki, Hiroaki Goto, Masakatsu Yanagimachi

{"title":"Chimerism analysis by ABO blood group genotyping with digital droplet PCR.","authors":"Takuya Naruto, Maiko Sagisaka, Mieko Ito, Akiko Hayashi, Naoyuki Miyagawa, Dai Keino, Tomoko Yokosuka, Fuminori Iwasaki, Hiroaki Goto, Masakatsu Yanagimachi","doi":"10.1007/s12185-024-03898-7","DOIUrl":"10.1007/s12185-024-03898-7","url":null,"abstract":"Objective: Chimerism analysis is an important post-transplant assessment for allogeneic hematopoietic stem cell transplant (HCT) recipients. Although various chimerism analysis techniques are already established, they are limited in terms of sensitivity, versatility, and turnaround time. Our objective was to develop a digital droplet polymerase chain reaction (ddPCR) assay for chimerism analysis using ABO gene polymorphisms as markers.Methods: Our new chimerism analysis method utilizes ddPCR to assess the ABO gene polymorphisms that encode the ABO blood genotype. ABO genotypes were determined in blood samples from 15 HCT recipients using the O panel (rs8176719) and B panel (rs8176746 and rs8176747).Results: The two panels distinguished six ABO genotypes (AA, AO, BB, BO, AB, and OO). The results of chimerism analysis using ABO genotypes with ddPCR were compatible with those of established methods, such as SRY gene analysis and the use of short tandem repeat markers via standard PCR. Our method could distinguish chimerism in 77% of donor and recipient combinations in the Japanese population.Conclusions: We developed a sensitive and rapid chimerism analysis method for HCT using ABO gene polymorphisms in ddPCR.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"397-402"},"PeriodicalIF":1.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142835633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A case of late-onset sinusoidal obstruction syndrome diagnosed histologically before meeting diagnostic criteria. 一例在符合诊断标准之前经组织学诊断的晚发性窦道阻塞综合征病例。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-03-01 Epub Date: 2025-01-05 DOI: 10.1007/s12185-024-03909-7

Takashi Kuroha, Tatsuo Furukawa, Seiichi Yoshikawa, Akane Kaihatsu, Hiroki Nemoto, Hiroyuki Usuda, Toshio Yano

引用次数: 0

Recent advances in understanding of pathogenesis and treatment development for diffuse large B-cell lymphoma and follicular lymphoma. 弥漫性大b细胞淋巴瘤和滤泡性淋巴瘤的发病机制和治疗进展。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-03-01 Epub Date: 2025-02-10 DOI: 10.1007/s12185-025-03939-9

Daisuke Ennishi

引用次数: 0

New classifications of B-cell neoplasms: a comparison of 5th WHO and International Consensus classifications. B 细胞肿瘤的新分类：第五次世界卫生组织分类与国际共识分类的比较。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-03-01 Epub Date: 2024-05-28 DOI: 10.1007/s12185-024-03781-5

Kennosuke Karube, Akira Satou, Seiichi Kato

{"title":"New classifications of B-cell neoplasms: a comparison of 5th WHO and International Consensus classifications.","authors":"Kennosuke Karube, Akira Satou, Seiichi Kato","doi":"10.1007/s12185-024-03781-5","DOIUrl":"10.1007/s12185-024-03781-5","url":null,"abstract":"In 2024, the World Health Organization (WHO) launched a new classification of lymphoid neoplasms, a revision of the previously used Revised 4th Edition of their classification (WHO-4R). However, this means that two classifications are now in simultaneous use: the 5th Edition of the WHO classification (WHO-5) and the International Consensus Classification (ICC). Instead of a comprehensive review of each disease entity, as already described elsewhere, this review focuses on revisions made in both the WHO-5 and ICC from WHO-4R and discrepancies between them regarding B-cell neoplasms. Similarities include cutaneous marginal zone lymphoma, cold agglutinin disease, non-primary effusion lymphoma-type effusion-based lymphoma, and gray zone lymphoma. Differences include plasma cell neoplasms, high-grade B-cell lymphoma (double hit lymphoma), follicular lymphoma, LPD with immune deficiency and dysregulation, extranodal large B-cell lymphoma, transformations of indolent B-cell lymphomas, and diffuse large B-cell lymphoma, not otherwise specified. Understanding the similarities and differences between the two latest classifications will aid daily diagnostic practice and future research on lymphoid neoplasms.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"331-341"},"PeriodicalIF":1.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141156857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent advances in understanding the biology of follicular lymphoma. 了解滤泡淋巴瘤生物学的最新进展。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-03-01 Epub Date: 2024-03-27 DOI: 10.1007/s12185-024-03764-6

Momoko Nishikori

{"title":"Recent advances in understanding the biology of follicular lymphoma.","authors":"Momoko Nishikori","doi":"10.1007/s12185-024-03764-6","DOIUrl":"10.1007/s12185-024-03764-6","url":null,"abstract":"Follicular lymphoma (FL), the most common indolent B-cell lymphoma, develops over decades before manifesting as overt disease. BCL2 overexpression by t(14;18) confers a survival advantage to B cells during the germinal center reaction, and abnormalities in epigenetic modifier genes lead to desynchronization of gene expression changes in germinal center B cells. Studies in mouse models have shown that BCL2 overexpression and epigenetic deregulation in B cells cooperatively promote lymphomagenesis. The immune microenvironment also plays an essential role in the biology of FL, and many molecular prognostic indicators based on the immune microenvironment have been proposed. However, high-risk gene signatures do not appear to be consistent between patients receiving different chemotherapies. FL cells frequently carry N-linked glycosylation motifs within the immunoglobulin gene, leading to chronic activation of the B-cell receptor (BCR). Recent evidence suggests that this chronic BCR signaling drives FL polarization toward a dark-zone phenotype and promotes clonal evolution. Since both epigenetic and post-transcriptional modifications of B cells have been implicated in the early stage of FL development, it may be possible to use novel non-chemotherapeutic approaches that interfere with the immunobiology in treatment or early prevention of FL.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"326-330"},"PeriodicalIF":1.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140305538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pseudo-Chediak-Higashi inclusions and Auer rods in a case of therapy-related acute monocytic leukemia. 治疗相关性急性单核细胞白血病一例伪chediak - higashi包涵体和Auer棒。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-03-01 Epub Date: 2024-12-30 DOI: 10.1007/s12185-024-03910-0

Radu Chiriac

引用次数: 0

Temporal changes in corticosteroid dose during ibrutinib treatment in patients with cGVHD and pulmonary involvement. 依鲁替尼治疗cGVHD和肺部受累患者期间皮质类固醇剂量的时间变化。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-03-01 Epub Date: 2024-12-10 DOI: 10.1007/s12185-024-03882-1

Masako Toyosaki, Shinichiro Machida, Daisuke Tomizawa, Masaya Okada, Masashi Sawa, Yasunori Ueda, Ai Omi, Yosuke Koroki, Takanori Teshima

{"title":"Temporal changes in corticosteroid dose during ibrutinib treatment in patients with cGVHD and pulmonary involvement.","authors":"Masako Toyosaki, Shinichiro Machida, Daisuke Tomizawa, Masaya Okada, Masashi Sawa, Yasunori Ueda, Ai Omi, Yosuke Koroki, Takanori Teshima","doi":"10.1007/s12185-024-03882-1","DOIUrl":"10.1007/s12185-024-03882-1","url":null,"abstract":"The GVH3001 study assessed the efficacy and safety of ibrutinib in Japanese patients with steroid-dependent or -refractory chronic graft-versus-host disease (cGVHD). However, the effects of ibrutinib on lung function and reduction in corticosteroid dose, which is a measurable factor associated with improved quality of life, could not be adequately assessed in patients who initially presented with lung involvement. This post hoc analysis aimed to evaluate temporal changes in daily corticosteroid dose, as well as effectiveness outcomes based on lung function and symptom burden (percent predicted forced expiratory volume in 1 s [%FEV1] and Lee cGVHD Symptom Scale lung subscale score, respectively) in the subgroup of patients with cGVHD who had lung involvement at baseline. Seven of the 19 patients in the GVH3001 study had lung involvement at baseline. The daily corticosteroid dose for cGVHD decreased in five of these patients, and %FEV1 remained relatively stable in two patients but increased to > 80% in one patient. Lee cGVHD Symptom Scale scores were relatively stable throughout the study in patients with lung involvement. Ibrutinib may allow corticosteroid dose reduction without worsening lung function or increasing symptom burden in previously treated patients with cGVHD and associated lung involvement.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"388-396"},"PeriodicalIF":1.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11861523/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142800668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current treatment approach and future perspectives in B cell lymphoma. B 细胞淋巴瘤的当前治疗方法和未来展望。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-03-01 Epub Date: 2024-11-21 DOI: 10.1007/s12185-024-03879-w

Nobuhiko Yamauchi, Dai Maruyama

{"title":"Current treatment approach and future perspectives in B cell lymphoma.","authors":"Nobuhiko Yamauchi, Dai Maruyama","doi":"10.1007/s12185-024-03879-w","DOIUrl":"10.1007/s12185-024-03879-w","url":null,"abstract":"Diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL) represent the two major subtypes of mature B cell lymphoma. A deeper understanding of tumor biology, as well as molecular classification characterized by targetable gene alterations, and the introduction of novel treatment options, including targeted drugs (e.g., antibody-drug conjugates and small molecules [e.g., Bruton tyrosine kinase inhibitor]) and immune therapies (e.g., chimeric antigen receptor [CAR] T cell therapy and bispecific antibody [BsAb]), has changed the treatment paradigms for DLBCL and FL. In clinical practice, however, treatment regimens are determined mainly based on prior treatment history, duration of response after previous treatment, patient age, and patient frailty because there have been few randomized trials to inform treatment selection for patients with relapsed or refractory disease and because there is no single prognostic index that guides suitable treatment for each patient. In this review, we summarize the treatment options for DLBCL and FL and discuss the treatment strategies for these two subtypes. We also discuss future perspectives for the treatment of these subtypes.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"342-355"},"PeriodicalIF":1.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142686904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Graft CD8⁺ T cells for improving event-free survival after T cell-replete haploidentical stem cell transplantation in children with hematological malignancies. 移植CD8+ T细胞提高儿童血液病患者T细胞单倍同型干细胞移植后无事件生存率

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-03-01 Epub Date: 2024-12-10 DOI: 10.1007/s12185-024-03900-2

Nobuhisa Takahashi, Kazuhiro Mochizuki, Atsushi Kikuta, Yoshihiro Ohara, Shingo Kudo, Kazuhiko Ikeda, Hitoshi Ohto, Hideki Sano

{"title":"Graft CD8+ T cells for improving event-free survival after T cell-replete haploidentical stem cell transplantation in children with hematological malignancies.","authors":"Nobuhisa Takahashi, Kazuhiro Mochizuki, Atsushi Kikuta, Yoshihiro Ohara, Shingo Kudo, Kazuhiko Ikeda, Hitoshi Ohto, Hideki Sano","doi":"10.1007/s12185-024-03900-2","DOIUrl":"10.1007/s12185-024-03900-2","url":null,"abstract":"T cell-replete haploidentical hematopoietic stem cell transplantation (TCR-haplo-HSCT) is a potentially curative therapy for pediatric intractable hematological malignancies due to its graft-versus-leukemia efficacy. This single-center cohort study examined the effects of graft composition (T cell type and dose) on pediatric TCR-haplo-HSCT outcomes in 32 children with relapsed/intractable hematological malignancies. Graft T cell composition was classified using flow cytometry. High graft CD8+ T cell doses reduced disease relapse and improved overall survival and event-free survival, but did not increase transplant-related mortality and the incidence of grade III/IV acute graft-versus-host disease. Doses of grafted CD3+, CD4+, and CD34+ T cells did not affect patient outcomes. Children with differing event-free survival times were divided by a graft CD8+ T cell dose cut-off of 2.03 × 108 kg-1. These findings revealed that grafted CD8+ T cells improved the graft-versus-leukemia effect of pediatric TCR-haplo-HSCT without increasing the risk of transplant-related mortality.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"403-410"},"PeriodicalIF":1.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142800665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0